Brielle Benyon, Assistant Managing Editor for CURE®, has been with MJH Life Sciences since 2016. She has served as an editor on both CURE and its sister publication, Oncology Nursing News. Brielle is a graduate from The College of New Jersey. Outside of work, she enjoys spending time with family and friends, CrossFit and wishing she had the grace and confidence of her toddler-aged daughter.
Follow Brielle on Twitter @Brielle_Benyon.
FDA Grants Regular Approval to Padcev for Pretreated Metastatic or Advanced Bladder Cancer
July 9th 2021Approximately 18 months after granting Padcev an accelerated approval, the Food and Drug Administration granted a regular approval to the treatment for certain previously treated patients with locally advanced or metastatic urothelial carcinoma.
FDA Rejects Approval of Oral Paclitaxel Plus Encequidar for Metastatic Breast Cancer: Here’s Why
March 5th 2021Last week, the Food and Drug Administration (FDA) was scheduled to make a decision on whether or not they would approve oral paclitaxel plus encequidar for the treatment of metastatic breast cancer. The agency decided not to approve the regimen, and issued a complete response letter outlining why.
FDA, Drug Manufacturer Pull Keytruda’s Indication for Small Cell Lung Cancer
March 5th 2021Merck – the manufacturer of Keytruda (pembrolizumab) – is pulling the immunotherapy drug’s indication for patients with metastatic small cell lung cancer whose disease progressed on or after platinum-based chemotherapy and one or more prior line of therapy.